SEC Form 4 · accession 0000899243-18-011575
Wave Life Sciences, Inc. · WVE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul Bolno
Officer — President and CEO · Director
Period of report
May 2, 2018
Accepted (ET)
May 4, 2018 · 8:04 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001631574
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | May 2, 2018 | M | 18,289 | $2.48 | A | 297,231 | D | |
| Ordinary Shares | May 2, 2018 | S | 18,289 | $45.00 | D | 278,942 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share Option (right to buy)F2 | $2.48 | May 2, 2018 | M | 18,289 | D | — | Mar 10, 2025 | Ordinary Shares | 18,289 | 404,489 | D |
Explanation of responses
- F1The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018.
- F2The share option represented a right to purchase a total of 422,778 ordinary shares that vest in thirty-six monthly installments beginning on December 12, 2014.